Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride.
HDL cholesterol
Metrnl
Metrnl tissue-specific knockout mice
dyslipidemia
serum lipid parameters
triglyceride
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
10
2019
accepted:
16
01
2020
revised:
14
01
2020
pubmed:
9
4
2020
medline:
17
8
2021
entrez:
9
4
2020
Statut:
ppublish
Résumé
Dyslipidemia is a risk factor for cardiovascular diseases and type 2 diabetes. Several adipokines play important roles in modulation of blood lipids. Metrnl is a recently identified adipokine, and adipose Metrnl participates in regulation of blood triglyceride (TG). In this study, we generated Metrnl global, intestine-specific and liver-specific knockout mice, and explored the effects of Metrnl on serum lipid parameters. Global knockout of Metrnl had no effects on serum lipid parameters under normal chow diet, but increased blood TG by 14%, and decreased total cholesterol (TC) by 16% and high density lipoprotein cholesterol (HDL-C) by 24% under high fat diet. Nevertheless, intestine-specific knockout of Metrnl did not alter the serum lipids parameters under normal chow diet or high fat diet. Notably, liver-specific knockout of Metrnl decreased HDL-C by 24%, TC by 20% and low density lipoprotein cholesterol (LDL-C) by 16% without alterations of blood TG and nonesterified fatty acids (NEFA) under high fat diet. But deficiency of Metrnl in liver did not change VLDL secretion and expression of lipid synthetic and metabolic genes. We conclude that tissue-specific Metrnl controls different components of blood lipids. In addition to modulation of blood TG by adipose Metrnl, blood HDL-C is regulated by liver Metrnl.
Identifiants
pubmed: 32265491
doi: 10.1038/s41401-020-0368-8
pii: 10.1038/s41401-020-0368-8
pmc: PMC7921638
doi:
Substances chimiques
Cholesterol, HDL
0
Nerve Growth Factors
0
Triglycerides
0
cometin protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1568-1575Références
Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25:567–79.
doi: 10.1016/S0828-282X(09)70715-9
Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71.
doi: 10.1210/jcem.86.3.7304
Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis 2012;30(Suppl 2):S127–45.
doi: 10.3233/JAD-2011-110599
Chen Z, Zhao GH, Zhang YK, Shen GS, Xu YJ, Xu NW. Research on the correlation of diabetes mellitus complicated with osteoporosis with lipid metabolism, adipokines and inflammatory factors and its regression analysis. Eur Rev Med Pharmacol Sci. 2017;21:3900–5.
pubmed: 28975973
Rahimlou M, Mirzaei K, Keshavarz SA, Hossein-Nezhad A. Association of circulating adipokines with metabolic dyslipidemia in obese versus non-obese individuals. Diabetes Metab Syndr. 2016;10:S60–5.
doi: 10.1016/j.dsx.2015.09.015
Coimbra S, Reis F. The protective role of adiponectin for lipoproteins in end-stage renal disease patients: relationship with diabetes and body mass index. Oxid Med Cell Longev. 2019;2019:3021785.
doi: 10.1155/2019/3021785
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39:1176–88.
doi: 10.1038/aps.2018.40
Habib SS, Eshki A, AlTassan B, Fatani D, Helmi H, AlSaif S. Relationship of serum novel adipokine chemerin levels with body composition, insulin resistance, dyslipidemia and diabesity in Saudi women. Eur Rev Med Pharmacol Sci. 2017;21:1296–302.
pubmed: 28387898
Korolczuk A, Beltowski J. Progranulin, a new adipokine at the crossroads of metabolic syndrome, diabetes, dyslipidemia and hypertension. Curr Pharm Des. 2017;23:1533–9.
doi: 10.2174/1381612823666170124114524
Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014;20:344–54.
doi: 10.1111/cns.12219
Jorgensen JR, Fransson A, Fjord-Larsen L, Thompson LH, Houchins JP, Andrade N, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol 2012;233:172–81.
doi: 10.1016/j.expneurol.2011.09.027
Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014;157:1279–91.
doi: 10.1016/j.cell.2014.03.065
Ushach I, Arrevillaga-Boni G, Heller GN, Pone E, Hernandez-Ruiz M, Catalan-Dibene J, et al. Meteorin-like/meteorin-beta is a novel immunoregulatory cytokine associated with inflammation. J Immunol 2018;201:3669–76.
doi: 10.4049/jimmunol.1800435
Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37:571–9.
doi: 10.1038/aps.2016.9
Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte metrnl antagonizes insulin resistance through PPARgamma signaling. Diabetes 2015;64:4011–22.
doi: 10.2337/db15-0274
Dooley TP, Miranda M, Jones NC, DePamphilis ML. Transactivation of the adenovirus EIIa promoter in the absence of adenovirus E1A protein is restricted to mouse oocytes and preimplantation embryos. Development. 1989;107:945–56.
pubmed: 2534379
Li ZY, Fan MB, Zhang SL, Qu Y, Zheng SL, Song J, et al. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol Sin. 2016;37:1458–66.
doi: 10.1038/aps.2016.70
Wan JF, Chu SF, Zhou X, Li YT, He WB, Tan F, et al. Ursodeoxycholic acid protects interstitial Cajal-like cells in the gallbladder from undergoing apoptosis by inhibiting TNF-alpha expression. Acta Pharmacol Sin. 2018;39:1493–500.
doi: 10.1038/aps.2017.206
Zheng SL, Li ZY, Zhang Z, Wang DS, Xu J, Miao CY. Evaluation of two commercial enzyme-linked immunosorbent assay kits for the detection of human circulating metrnl. Chem Pharm Bull. 2018;66:391–8.
doi: 10.1248/cpb.c17-00846
Ge MX, Niu WX, Ren JF, Cai SY, Yu DK, Liu HT, et al. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. Acta Pharmacol Sin. 2019;40:895–907.
doi: 10.1038/s41401-018-0195-3
Wang X, Xu TY, Liu XZ, Zhang SL, Wang P, Li ZY, et al. Discovery of novel inhibitors and fluorescent probe targeting NAMPT. Sci Rep. 2015;5:12657.
doi: 10.1038/srep12657
Mobin MB, Gerstberger S, Teupser D, Campana B, Charisse K, Heim MH, et al. The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation. Nat Commun 2016;7:12848.
doi: 10.1038/ncomms12848
Hussain MM. Intestinal lipid absorption and lipoprotein formation. Curr Opin Lipido. 2014;25:200–6.
doi: 10.1097/MOL.0000000000000084
Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45:948–53.
doi: 10.1194/jlr.M300520-JLR200
Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984;251:58–66.
doi: 10.1038/scientificamerican1184-58